Relapsing-Remitting Multiple Sclerosis Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Relapsing-Remitting Multiple Sclerosis Pipeline Insight 2025' report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Relapsing-Remitting Multiple Sclerosis pipeline landscape. It covers the Relapsing-Remitting Multiple Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Relapsing-Remitting Multiple Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Relapsing-Remitting Multiple Sclerosis Pipeline Report to explore emerging therapies, key Relapsing-Remitting Multiple Sclerosis Companies, and future Relapsing-Remitting Multiple Sclerosis treatment landscapes @ Relapsing-Remitting Multiple Sclerosis Pipeline Outlook Report
Key Takeaways from the Relapsing-Remitting Multiple Sclerosis Pipeline Report
In June 2025, Novartis Pharmaceuticals announced a study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy. This study will also look at whether an elevated serum neurofilament light (NfL) level predicts enhanced benefit from a switch to ofatumumab.
In June 2025, Celgene conducted a study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).
DelveInsight's Relapsing-Remitting Multiple Sclerosis pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Relapsing-Remitting Multiple Sclerosis treatment.
The leading Relapsing-Remitting Multiple Sclerosis Companies such as Immunic AG, Sanofi, Anokion, RemeGen, HuniLife Biotechnology, Biogen, Clene Nanomedicine, Novartis, Celltrion, Imcyse SA, Takeda and others.
Promising Relapsing-Remitting Multiple Sclerosis Therapies such as TMP001, Rebif®, Avonex®, dimethyl fumarate, BAF312, IMCY-0141, Ocrelizumab, and others.
Discover how the Relapsing-Remitting Multiple Sclerosis treatment paradigm is evolving. Access DelveInsight's in-depth Relapsing-Remitting Multiple Sclerosis Pipeline Analysis for a closer look at promising breakthroughs @ Relapsing-Remitting Multiple Sclerosis Clinical Trials and Studies
Relapsing-Remitting Multiple Sclerosis Emerging Drugs Profile
IMU-838: Immunic AG
Vidofludimus calcium is an orally administered investigational small molecule drug being developed for chronic inflammatory and autoimmune diseases, currently in late-stage clinical trials for multiple sclerosis (MS). Uniquely, vidofludimus calcium's first-in-class, dual mode of action combines neuroprotective, anti-inflammatory and anti-viral effects to target the complex pathophysiology of MS. As a selective immune modulator, it activates the neuroprotective transcription factor, nuclear receptor-related 1 (Nurr1), which provides direct and indirect neuroprotective effects. Additionally, vidofludimus calcium achieves anti-inflammatory and anti-viral effects through highly selective inhibition of the enzyme dihydroorotate dehydrogenase (DHODH). Currently, the drug is in Phase III stage of its development for the treatment of Relapsing-Remitting Multiple Sclerosis.
IMCY-0141: Imcyse SA
IMCY-0141 Imotope™ is designed based on MOG (Myelin Oligodendrocyte Glycoprotein) with the aim to halt the progression of multiple sclerosis (MS) by stopping the body's immune system from attacking the central nervous system and disrupting undesirable autoimmune responses that drive the destruction of the myelin sheath protecting the nerves. IMCY-0141 has shown promising results in several MS preclinical models, demonstrating an immune response that supports the proposed mode of action and inducing a memory response so that the treatment effect is long-lasting and requires less frequent dosing regimens. Also, if treatment is begun early enough, it has the potential to allow patients to live with minimal impact from the disease. Currently, the drug is in Phase I/II stage of its development for the treatment of Relapsing-Remitting Multiple Sclerosis.
ANK-700: Anokion SA
ANK-700 is an investigational therapy developed by Anokion for the treatment of Relapsing-Remitting Multiple Sclerosis (RRMS). It employs a novel approach known as an ""inverse vaccine,"" aiming to re-educate the immune system to recognize specific myelin proteins as ""self,"" thereby preventing autoimmune attacks on the central nervous system. This strategy seeks to reduce neuroinflammation while preserving overall immune function. Anokion's approach utilizes its proprietary immune tolerance platform, which targets natural pathways in the liver to restore immune tolerance. This liver-targeted antigen strategy effectively expands antigen-specific regulatory T-cells in vivo, offering therapeutic potential across various inflammatory conditions, including multiple sclerosis. ANK-700's innovative mechanism and encouraging early clinical data position it as a promising candidate for future disease-modifying therapies in RRMS. Currently, the drug is in Phase I stage of its development for the treatment of Relapsing-Remitting Multiple Sclerosis.
The Relapsing-Remitting Multiple Sclerosis pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Relapsing-Remitting Multiple Sclerosis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Relapsing-Remitting Multiple Sclerosis Treatment.
Relapsing-Remitting Multiple Sclerosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Relapsing-Remitting Multiple Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Relapsing-Remitting Multiple Sclerosis market.
Get a detailed analysis of the latest innovations in the Relapsing-Remitting Multiple Sclerosis pipeline. Explore DelveInsight's expert-driven report today! @ Relapsing-Remitting Multiple Sclerosis Unmet Needs
Relapsing-Remitting Multiple Sclerosis Companies
Immunic AG, Sanofi, Anokion, RemeGen, HuniLife Biotechnology, Biogen, Clene Nanomedicine, Novartis, Celltrion, Imcyse SA, Takeda and others.
Relapsing Remitting multiple sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Relapsing-Remitting Multiple Sclerosis Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Download DelveInsight's latest report to gain strategic insights into upcoming Relapsing-Remitting Multiple Sclerosis Therapies and key Relapsing-Remitting Multiple Sclerosis Developments @ Relapsing-Remitting Multiple Sclerosis Market Drivers and Barriers, and Future Perspectives
Scope of the Relapsing-Remitting Multiple Sclerosis Pipeline Report
Coverage- Global
Relapsing-Remitting Multiple Sclerosis Companies- Immunic AG, Sanofi, Anokion, RemeGen, HuniLife Biotechnology, Biogen, Clene Nanomedicine, Novartis, Celltrion, Imcyse SA, Takeda and others.
Relapsing-Remitting Multiple Sclerosis Therapies- TMP001, Rebif®, Avonex®, dimethyl fumarate, BAF312, IMCY-0141, Ocrelizumab, and others.
Relapsing-Remitting Multiple Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Relapsing-Remitting Multiple Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Relapsing-Remitting Multiple Sclerosis drug development? Find out in DelveInsight's exclusive Relapsing-Remitting Multiple Sclerosis Pipeline Report—access it now! @ Relapsing-Remitting Multiple Sclerosis Emerging Drugs and Major Companies
Table of Content
Introduction
Executive Summary
Relapsing-Remitting Multiple Sclerosis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Relapsing-Remitting Multiple Sclerosis– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
IMU-838: Immunic AG
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Telitacicept: RemeGen
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ANK700: Anokion
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Relapsing-Remitting Multiple Sclerosis Key Companies
Relapsing-Remitting Multiple Sclerosis Key Products
Relapsing-Remitting Multiple Sclerosis- Unmet Needs
Relapsing-Remitting Multiple Sclerosis- Market Drivers and Barriers
Relapsing-Remitting Multiple Sclerosis- Future Perspectives and Conclusion
Relapsing-Remitting Multiple Sclerosis Analyst Views
Relapsing-Remitting Multiple Sclerosis Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/relapsing-remitting-multiple-sclerosis-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Is It Time to Just Buy Nike Stock as a Turnaround Takes Hold?
It's been frustrating to be a Nike (NYSE: NKE) investor the past few years, but investors cheered after new CEO Elliott Hill indicated that the worst was now behind the company after it reported its fiscal fourth quarter results. Nike shares surged on the results, which topped low expectations, although the stock is still down on the year and more than 20% lower over the past five years. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Let's delve into Nike's recent earnings to see why now is a good time to pick up shares in the iconic sneaker and apparel maker. The worst is over Hill, who has been on the job for less than a year, has been working hard to help turn around Nike's business following the missteps of former CEO John Donahoe. Hill's predecessor neglected innovation and pushed the company's classic footwear segment, which consists of brands like Air Jordan and Air Force 1. He also made a big direct-to-consumer push while neglecting important wholesale relationships. Hill has been working to rewind the damage done by Donahoe through his Win Now action plan. The main tenet of his plan is to return Nike to its innovation roots. He has reorganized the business to drive sports-specific innovation across its three main brands: Nike, Jordan, and Converse. The company has seen some early traction with new innovation, with its Vomero 18 running shoe becoming a $100 million-plus franchise with strong sell-through just 90 days after launch. The company is also working to mend its relationship with wholesalers. On this end, it recently announced a new partnership with Amazon, where the e-commerce giant will carry a select assortment of Nike footwear, apparel, and accessories. Nike also hired retail marketing, visual merchandising, and account managers to work with large wholesalers to help with their presentations and create better consumer connections. In addition, the company is looking to implement sharper marketplace segmentation in order to serve its customers at different price points. At the same time, it is looking to position Nike Digital and Nike Direct as premium destinations. This means you might be able to get some lower-priced Nike products at a retailer like Kohl's, while Nike will have its high-end products with the newest technology on its apps and in its stores. While Nike's actual results were still weak, Hill said it's time to turn the page and that he expects Nike's results to improve moving forward. For fiscal Q4, Nike's revenue declined 12% to $11.1 billion, with Nike brand revenue down 11% to $10.8 billion. Nike Direct revenue sank 14% to $4.7 billion, as digital sales collapsed 26%. This is largely due to the company repositioning its digital app as a premier destination. Wholesale revenue, meanwhile, dropped 9% to $6.4 billion. China remained a weak spot, with revenue sinking 21% in the quarter to $1.5 billion. Nike has been heavily discounting in China to reset its inventory. North America revenue dipped 11% to $4.7 billion, with apparel sales down 7% and footwear revenue falling 13%. EMEA (Europe, Middle East, and Africa) sales sank 9%, while Asia Pacific and Latin America sales decreased by 8%. Heavy discounting to clear inventory continued to weigh on Nike's gross margins, which fell 440 basis points to 40.3%. Between declining sales and gross margins, its earnings per share (EPS) plunged 86% in the quarter to $0.14. The company said that tariffs would be a significant new cost headwind, representing an estimated $1 billion in gross costs. It said the tariffs would hurt its gross margin by 75 basis points this fiscal year, with the bigger impact in the first half. It is currently working with suppliers and retail partners to mitigate the costs and impact on consumers. Is Nike stock a buy? While Nike's progress has not yet shown up in its results, Hill is helping lay the groundwork for the company to get back on track. He's been leaning into innovation, rebuilding wholesale partnerships, repositioning Nike's app and stores as premium destinations, and working to segment the brand into both premium and core offerings depending on the channel. While the stock trades at a pretty hefty valuation, with a forward price-to-earnings (P/E) ratio of around 39 times analysts' 2026 estimates, that's largely because Nike's earnings have been depressed. If Hill can get Nike's EPS back to the $3.73 it was in fiscal year 2024, the stock would trade at under 20 times earnings. Nike still has work to do, but now could be a good opportunity to buy the stock when the company is showing signs of a turnaround and the stock is still down on the year. Should you invest $1,000 in Nike right now? Before you buy stock in Nike, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nike wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor 's total average return is1,062% — a market-crushing outperformance compared to177%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 23, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Geoffrey Seiler has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon and Nike. The Motley Fool has a disclosure policy.
Globe and Mail
an hour ago
- Globe and Mail
Anosh Laboratory Technologies Unveils Advanced Platform to Improve Diagnostic Accuracy and Prevent Testing Fraud
Chicago, Illinois--(Newsfile Corp. - June 29, 2025) - Anosh Laboratory Technologies has announced the upcoming release of a next-generation diagnostic platform developed to enhance laboratory testing precision and strengthen fraud prevention across the clinical testing ecosystem. Dr. Anosh Ahmed To view an enhanced version of this graphic, please visit: The proprietary system-under development since 2020-was initiated under the leadership of Dr. Anosh Ahmed, founder of Anosh Laboratory Technologies, in direct response to the operational gaps exposed during the COVID-19 pandemic. Designed to support both public and private sector laboratories, the technology combines high-throughput testing capabilities with built-in compliance, real-time data verification, and traceability controls. "Our team set out to close critical gaps in laboratory testing infrastructure-specifically around accuracy, accountability, and fraud detection," said Dr. Anosh Ahmed. "This platform reflects five years of focused R&D and cross-functional collaboration." Built for scalability, the system is compatible with existing lab workflows and optimized for rapid deployment in infectious disease and high-volume diagnostic environments. Its modular architecture allows for customization based on lab size, regulatory requirements, and test volumes. A comprehensive technical white paper detailing the system design, performance metrics, and application roadmap will be released in the coming weeks. Regulatory submissions are expected to follow shortly thereafter. The launch aligns with Dr. Anosh Ahmed's ongoing commitment to advancing healthcare infrastructure through innovation, transparency, and operational integrity. His work through Anosh Laboratory Technologies continues to bridge clinical needs with long-term system sustainability. This release marks a key milestone in Anosh Laboratory Technologies' broader mission to modernize diagnostic systems and reinforce trust across healthcare delivery. About Anosh Laboratory Technologies Anosh Laboratory Technologies is a Chicago-based diagnostics and health technology company founded by Dr. Anosh Ahmed, focused on advancing lab systems through innovation, compliance automation, and scalable solutions for global health challenges.
Globe and Mail
2 hours ago
- Globe and Mail
Julius Randle, T-Wolves finalizing reported three-year, $100 million deal
Julius Randle and the Minnesota Timberwolves are finalizing a new deal that could keep him with the club through the 2027-28 season, a person with knowledge of the agreement said Sunday. The final year of the deal will be at Randle's option and, if it is exercised, could push the total value of the contract to $US100-million, the person said. The person spoke to The Associated Press on condition of anonymity because neither side announced the agreement. ESPN and The Athletic first reported the agreement. Randle had a $US30.9-million player option for this coming season and could have been an unrestricted free agent in 2026. He averaged 18.7 points and 7.1 rebounds per game this past season, his first with the Timberwolves, and helped the team make the Western Conference finals. Randle was one of the primary pieces in the trade last fall that sent Karl-Anthony Towns from Minnesota to New York. Randle had spent five seasons with the Knicks before that trade. A three-time All-Star, Randle has averaged 19 points and 9.1 rebounds per game in 11 seasons with the Timberwolves, Knicks, New Orleans and the Los Angeles Lakers.
